News | 22 December 2024
KRAIBURG TPE's solutions upraises healthcare products for higher functionality
The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,
The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
The company has received the GMP Certification after successful closure of the inspection
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
This facility marks a significant milestone in transforming the global food industr
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
SPARC to receive 55% equity in Tiller Therapeutics
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Harnessing advanced data analysis for early detection, prevention and better outcomes
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Subscribe To Our Newsletter & Stay Updated
